Your browser doesn't support javascript.
loading
CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy.
Russo, Giuseppina T; Corigliano, Gerardo; Arturi, Franco; Cavallo, Maria Gisella; Bette, Cristiano; Mannucci, Edoardo.
Afiliação
  • Russo GT; Department of Clinical and Experimental Medicine, "Gaetano Martino" University Hospital, Messina, Italy. Electronic address: girusso@unime.it.
  • Corigliano G; Diabetology Service, Italian Diabetes Association, Napoli, Italy.
  • Arturi F; Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
  • Cavallo MG; Department of Experimental Medicine, Sapienza University, Rome, Italy.
  • Bette C; Novo Nordisk, Rome, Italy.
  • Mannucci E; Careggi University Hospital, Firenze, Italy.
Nutr Metab Cardiovasc Dis ; 32(5): 1195-1201, 2022 05.
Article em En | MEDLINE | ID: mdl-35260306
ABSTRACT
BACKGROUND AND

AIMS:

The prevalence of type 2 diabetes (T2D) in Italy is increasing and cardiovascular disease (CVD) represents the leading cause of death in this population. CAPTURE was a multinational, multicentre, non-interventional, cross-sectional study assessing the prevalence of CVD, atherosclerotic CVD (AsCVD) and CVD subtypes among patients with T2D, across 13 countries. Here we report the results from Italy. METHODS AND

RESULTS:

Overall, 816 patients with T2D (median age, 69 years [interquartile range 62-75]; median duration of diabetes, 11.2 years [interquartile range 5.7-18.7]) were recruited during routine clinical visits at secondary care centres in Italy between December 2018-September 2019. The prevalence of CVD was estimated at 38.8%, largely accounted for by AsCVD (33.1%). The most prevalent CVD subtype was coronary heart disease (20.8%), followed by carotid artery disease (13.2%). Most patients (85.9%) were prescribed oral glucose-lowering agents (GLAs), particularly biguanide (76.7%). Insulin use was higher in patients with CVD (41.3%) than in patients without CVD (32.9%). Sodium-glucose co-transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were prescribed to 20.2% vs 14.6%, and 14.5% vs 16.6% of patients with CVD compared to those without CVD, respectively.

CONCLUSION:

The results show that, in Italy, more than one in three patients with T2D attending secondary care centres have CVD, 85% of whom have AsCVD, yet only a minority are treated with SGLT2is and GLP-1 RAs, in discordance with the recommendations of current national and international guidelines.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article